Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Experimental and Therapeutic Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-0981 Online ISSN: 1792-1015
Journal Cover
August-2015 Volume 10 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
August-2015 Volume 10 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Recombinant ING4 suppresses the migration of SW579 thyroid cancer cells via epithelial to mesenchymal transition

  • Authors:
    • Chuan‑Jiang Wang
    • Dong Yang
    • Ying‑Wei Luo
  • View Affiliations / Copyright

    Affiliations: Department of Vascular and Thyroid Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
  • Pages: 603-607
    |
    Published online on: May 22, 2015
       https://doi.org/10.3892/etm.2015.2515
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Thyroid cancer is a common endocrine malignancy that has rapidly increased in global incidence. Inhibitor of growth 4 (ING4) has been identified in various types of carcinoma; however, to the best of our knowledge, no previous studies have investigated the effects of ING4 on thyroid cancer. In the present study, SW579 thyroid cancer cells were treated with recombinant ING4 protein, and the results confirmed that recombinant ING4 protein was able to reduce the rate of proliferation, increase the rate of apoptosis and inhibit the mobility of SW579 cells. These results were obtained using a colony formation, fluoroscein isothiocyanate/propidium iodide double staining and Transwell assays, respectively. Furthermore, in the western blot analysis assays, ING4 was demonstrated to inhibit the Wnt/β catenin signaling pathway and epithelial to mesenchymal transition (EMT). Therefore, the present study demonstrated the antitumor activities of recombinant ING4 and identified ING4 could inhibit EMT in thyroid cancer cell. However, additional studies are required to confirm these results in other cell types.

Introduction

Inhibitor of growth 4 (ING4) is located on chromosome 12p13 and encodes a 249-amino acid protein containing a novel conserved region in the N terminus, a nuclear localization signal in the central region and a highly conserved plant homeodomain in the C terminus (1). Downregulation of ING4 has been reported in various types of cancer, including hepatocellular and gastric carcinomas, and breast, colon and lung cancers (2–6). Previous studies have also demonstrated that ING4 is involved in a variety of cellular processes, including cell proliferation, apoptosis, migration, angiogenesis and the DNA damage response (7–10).

In epithelial to mesenchymal transition (EMT), epithelial cells transform into a mesenchymal phenotype, which involves an increase in fibroid morphology, invasiveness and resistance to apoptosis, as well as an increase in extracellular matrix components (11). Increasing evidence indicates that cancer cells acquire invasive properties by EMT (12–15).

Thyroid cancer is a common endocrine malignancy that has exhibited a rapid increase in global incidence in recent decades (16). However, the roles of recombinant ING4 protein in thyroid cancer remain unclear. Therefore, in the present study, the effect of recombinant ING4 on the growth, mobility and apoptosis of thyroid cancer cells was investigated, as well as the association between ING4 and EMT.

Materials and methods

Cell culture

SW579, a human thyroid cancer cell line, was purchased from the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). The cells were cultured at 37°C with 5% (v/v) CO2 in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Gaithersburg, MD, USA), which was supplemented with 10% (v/v) fetal calf serum (FCS; Life Technologies) and antibiotics (100 µM penicillin and 100 µM streptomycin; Sigma-Aldrich, Carlsbad, CA, USA).

Colony formation assay

Cells were seeded at 200 cells per well in 24-well tissue culture plates for 24 h under 5% CO2 at 37°C. Subsequently, the cells were treated with various concentrations (0, 50, 100, 150, 200 or 250 ng/ml) of recombinant ING4 protein (Sino Biological, Inc., Beijing, China), and the plates were incubated for 1 week in a humidified incubator at 37°C. Colonies were stained with 0.05% crystal violet (Beyotime Institute of Biotechnology, Shanghai, China) containing 50% methanol, and counted. The colonies were counted in four or five random fields of vision for each of the duplicate samples using a CX71 microscope (Olympus Corporation, Tokyo, Japan) at a magnification of ×100. The IC50 value of the recombinant ING4 protein was determined and for use in later experiments.

Flow cytometric analysis of the apoptosis rate

To detect the rate of apoptosis, an annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (KeyGen, Nanjing, China) was used in accordance with the manufacturer's instructions. The samples were immediately analyzed on a FACSCalibur flow cytometer (Becton-Dickinson Medical Devices, Shanghai, China).

Transwell assay

A Transwell migration assay was performed using the Boyden chamber (8 µM pore size; polycarbonate membrane; Cell Biolabs, San Diego, CA, USA). The cells were resuspended in FCS-free DMEM to a concentration of 3×105 cells/ml. The upper chamber was loaded with 100 µl cell suspension, while the lower chamber was loaded with 600 µl DMEM containing 10% FCS. Following incubation for 12 h in normal culture conditions, the filter was fixed in 4% paraformaldehyde (Sigma-Aldrich) and stained with crystal violet. The cells on the upper side of the filter were removed using a cotton swab, and the cells that had migrated to the undersurface of the membrane were counted using a light microscope (6XC; Shanghai Guangmai Instruments Ltd., Shanghai, China). In total, 10 microscopic fields (magnification, ×400) were randomly selected for the counting of the cells.

Gelatin zymography

A gelatin zymography assay was performed according to the methods outlined by Song and Zhao (17). Briefly, 50 mg protein was applied to 10% polyacrylamide gels, with 1% gelatin incorporated as a substrate for the gelatinolytic proteases. Subsequent to running the gel, the sodium dodecyl sulfate (SDS) was removed by washing twice in 2.5% Triton X-100 for 30 min. The gels were incubated overnight in a zymography development buffer, which contained 50 mM Tris-HCl (pH 7.4), 2 mM NaN3 and 5 mM CaCl2. Following development, the gels were stained for 3 h in 45% methanol/10% glacial acetic acid containing 1% (w/v) Coomassie Brilliant Blue R-250 (Beyotime Institute of Biotechnology), and subsequently partially destained with the same solution without dye. The gelatinolytic activity of each matrix metalloproteinase (MMP) was qualitatively evaluated as a clear band against the blue-stained gelatin background.

Chick chorioallantoic membrane (CAM) assay

A CAM assay was conducted according to the methods outlined by Lokman et al (18). Chick eggs (Dezhou Food Imp & Exp Co. Ltd., Dezhou, China) were incubated in a MultiQuip incubator (MultiQuip, Austral, NSW, Australia) at 37°C with 60% humidity. Under aseptic conditions, a small window was made in the shell on day 3 of chick embryo development to observe the underlying vasculature. The window was resealed with adhesive tape and the eggs were returned to the incubator until day 11 of chick embryo development. On day 11, all three groups of SW579 cells were labeled with CellTracker™ Green 5-chloromethylfluorescein diacetate (Invitrogen Life Technologies, Carlsbad, CA, USA) in suspensions (1×106 cells/well) and mixed with growth factor reduced Matrigel (8.9 mg/ml; BD Biosciences, Franklin Lakes, NJ, USA) to a total volume of 30 µl. Subsequently, the Matrigel grafts were placed on top of the CAM, and the eggs were resealed and returned to the incubator for 72 h until day 14 (n=6 chicken embryos per cell line; SW579, PBS and ING4). Matrigel grafts with the surrounding CAM were harvested from each embryo, fixed with 4% paraformaldehyde for 24 h and embedded in Optimum Cutting Temperature compound (Tissue-Tek; Sakura Finetek USA, Inc., Torrance, CA, USA). The samples were stored at −80°C, and frozen samples were cut into 5-µm sections using a Cryomicrotome CM 1850 (Leica Microsystems, Bannockburn, IL, USA). Images were acquired using an Olympus fluorescence microscope (Olympus Corporation, Osaka, Japan).

Preparation of nuclear and cytoplasmic protein extracts

Nuclear and cytoplasmic protein fractions were isolated using a CelLytic™ NuCLEAR™ Extraction kit (Sigma-Aldrich), according to the manufacturer's instructions. Protein concentrations were determined using a bicinchoninic acid protein assay, with bovine serum albumin used as a standard (Pierce Biotechnology, Inc., Rockford, IL, USA).

Western blot analysis

Protein extracts were resolved by SDS-PAGE, which was followed by electrotransfer to nitrocellulose membranes (Bio-Rad Laboratories, Inc., Philadelphia, PA, USA). Following a blocking step using 5% milk in Tris-buffered saline with Tween® 20, the membranes were incubated with primary antibodies at room temperature overnight (Table I). Subsequently, the membranes were developed and visualized with enhanced chemiluminescence (Thermo Fisher Scientific, Waltham, MA, USA). Secondary monoclonal antibodies were purchased from the Beyotime Institute of Biotechnology. The secondary monoclonal antibodies included anti-mouse IgG (#A0216), anti-rabbit IgG (#A0239) and anti-goat IgG (#A0181). The membranes were incubated with secondary antibodies for 2 h at room temperature.

Table I.

Antibodies used in western blot analysis.

Table I.

Antibodies used in western blot analysis.

ProteinManufacturerCatalog numberDilution
E-cadherinSanta Cruz Biotechnologyasc-78701:200
VimentinSanta Cruz Biotechnologyasc-62601:200
N-cadherinSanta Cruz Biotechnologyasc-79391:200
Anti-Wnt5bAbcambab949141:200
LRP6Santa Cruz Biotechnologyasc-179821:200
p-LRP6 (Ser1490)Cell Signaling Technologyc33951:200
Axin2Cell Signaling Technologyc21511:200
GSK-3βSanta Cruz Biotechnologyasc-814621:200
β-cateninSanta Cruz Biotechnologyasc-14961:200
β-actinSanta Cruz Biotechnologyasc-1306561:1,000
β-tubulinSanta Cruz Biotechnologyasc-555261:500

a Dallas, TX, USA

b Hong Kong, P.R. China

c Beverly, MA, USA. LRP, low-density lipoprotein receptor-related protein; GSK, glycogen synthase kinase.

Statistical analysis

Numerical data are expressed as the mean ± standard deviation, and differences among the mean values were evaluated using the Student's t-test. Statistical analyses were conducted using SPSS software (version 11.0; SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Antitumor effects of recombinant ING4 protein on SW579 cells

Cell viability was assessed using the colony formation assay. As shown in Fig. 1A, the proliferative rate of the cells in the recombinant ING4-treated group was inhibited significantly in a dose-dependent manner (P<0.05). The IC50 value of the recombinant ING4 protein was determined to be 192.5 ng/ml. When compared with the untreated SW579 cells or the phosphate-buffered saline-treated cells, the apoptotic ratio of the cells following treatment with recombinant ING4 protein was observed to increase significantly using annexin V-FITC and propidium iodide double staining (P<0.05; Fig. 1B). In addition, the Transwell assay revealed that cell motility was significantly decreased in the recombinant ING4 protein-treated group, as compared with the untreated cells (P<0.05; Fig. 1C). The activity levels of MMP-2 and −9 were shown to be inhibited by ING4 protein in SW579 cells (Fig. 1D). Additionally, using the CAM model, ING4 protein was demonstrated to inhibit SW579 cells from escaping primary tumor sites and scattering among blood vessels (Fig. 1E).

Figure 1.

Antitumor activities of ING4 in SW579 cells. (A) Proliferation ratio of SW579 cells treated with recombinant ING4 protein was measured using the colony formation assay. (B) Apoptotic ratio of cells was analyzed by double staining with annexin-V FITC/PI. (C) Transwell assays were performed to detect the mobility of the SW579 cells treated with recombinant ING4 protein. (D) Gelatinolytic activity levels of MMP-2 and -9, secreted from the SW579 cells, were analyzed by zymography. (E) Invasive GFP-labeled SW579 cells were visualized intravascularly. SW579, untreated SW579 cells; PBS, PBS treated SW579 cells; ING4, recombinant ING4 protein treated SW579 cells; ING, inhibitor of growth; FITC, fluorescein isothiocyanate; PI propidium iodide; MMP, matrix metalloproteinase; PBS, phosphate-buffered saline; GFP, green fluorescent protein.

Mechanisms of recombinant ING4 protein-induced apoptosis and inhibited mobility in SW579 cells

To identify the mechanisms underlying the effects of recombinant ING4 protein in SW579 cells, the expression levels of various proteins were detected by western blot analysis. When compared with the untreated cells, the ING4-treated SW579 cells exhibited a higher expression level of the epithelial marker, E-cadherin, while lower expression levels of the mesenchymal markers, vimentin and N-cadherin, were detected (Fig. 2). Notably, changes in Wnt5b expression were observed in the SW579 cells following treatment with ING4. Furthermore, the western blot analysis assays detected a significant inhibition of low-density lipoprotein receptor-related protein 6 expression and phosphorylation following treatment with ING4 (Fig. 2). A concomitant increase in Axin2 and glycogen synthase kinase-3β expression was detected in the ING-treated SW579 cells, as compared with the control groups, while decreased expression levels of nuclear and cytosolic β-catenin were observed (Fig. 2). Pathway enrichment analysis was performed in the Kyoto Encyclopedia of Genes and Genomes database (Institute for Chemical Research, Kyoto University, Kyoto, Japan; Institute of Medical Science, University of Tokyo, Tokyo, Japan), and the analysis results revealed that the Wnt signaling pathway was involved in the antitumor effects of ING4 (Fig. 3).

Figure 2.

Effects of ING4 protein on the Wnt signaling pathway, as shown by western blot analysis. Cell lysates were electrophoresed and the expression levels of Wnt-associated proteins were detected using their specific antibodies. LRP, low-density lipoprotein receptor-related protein; GSK, glycogen synthase kinase; PBS, phosphate-buffered saline; ING, inhibitor of growth.

Figure 3.

Map of the Wnt signaling pathway, which includes at least three Wnt signaling pathways, namely the canonical pathway, the planar cell polarity pathway and the Wnt/Ca2+ pathway.

Discussion

As previously discussed, ING4 is involved in cell proliferation, apoptosis, migration, angiogenesis and the DNA damage response (7–10). Consistent with these previous studies, the present study confirmed the ability of ING4 to inhibit cell proliferation and mobility, and induce apoptosis in SW579 cells. To the best of our knowledge, although ING4 is not observed in a number of cancer types, this is the first study to demonstrate the antitumor roles of ING4 in thyroid cancer.

The primary finding of the present study was the involvement of the Wnt signaling pathway in the mechanism underlying the effects of ING4. Canonical Wnt/β-catenin signaling directly alters gene expression, and has been shown to be a key regulator of cell proliferation, differentiation and apoptosis in a variety of cancer types (19,20). Abnormal activation of the Wnt/β-catenin signaling pathway and the subsequent upregulation of β-catenin has also been associated with the development of breast cancer (21). In the present study, ING4 was demonstrated to suppress Wnt5b expression in SW579 cells. The inhibition of Wnt5b expression results in decreased cytosolic accumulation of β-catenin, followed by reduced β-catenin translocation to the nucleus (22). Furthermore, the present results indicated that targeting the β-catenin pathways may suppress the mobility of SW579 cells, which is associated with EMT. E-cadherin is known to anchor and sequester β-catenin in the membrane to prevent activation; thus, the activation of β-catenin signaling may result from the downregulation of E-cadherin at EMT (22). E-cadherin expression has also been shown to be upregulated following decreased β-catenin expression (22).

In conclusion, the results of the present study have confirmed the antitumor activities and mechanisms of ING4-induced apoptosis in SW579 cells. These results provide initial evidence indicating the potential of ING4 as a therapeutic target for thyroid cancer.

Acknowledgements

The authors thank Miss. Wei Wang for the provision of valuable comments.

References

1 

Shiseki M, Nagashima M, Pedeux RM, et al: p29ING4 and p28ING5 bind to p53 and p300 and enhance p53 activity. Cancer Res. 63:2373–2378. 2003.PubMed/NCBI

2 

Byron SA, Min E, Thal TS, et al: Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancer. PLoS One. 7:e468232012. View Article : Google Scholar : PubMed/NCBI

3 

Zeng ZL, Li FJ, Gao F, Sun DS and Yao L: Upregulation of miR-650 is correlated with downregulation of ING4 and progression of hepatocellular carcinoma. J Surg Oncol. 107:105–110. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Li M, Jin Y, Sun WJ, et al: Reduced expression and novel splice variants of ING4 in human gastric adenocarcinoma. J Pathol. 219:87–95. 2009. View Article : Google Scholar : PubMed/NCBI

5 

Lou C, Jiang S, Guo X and Dong XS: ING4 is negatively correlated with microvessel density in colon cancer. Tumour Biol. 33:2357–2364. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Wang QS, Li M, Zhang LY, et al: Down-regulation of ING4 is associated with initiation and progression of lung cancer. Histopathology. 57:271–281. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Li X, Zhang Q, Cai L, et al: Inhibitor of growth 4 induces apoptosis in human lung adenocarcinoma cell line A549 via Bcl-2 family proteins and mitochondria apoptosis pathway. J Cancer Res Clin Oncol. 135:829–835. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Shen JC, Unoki M, Ythier D, et al: Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res. 67:2552–2558. 2007. View Article : Google Scholar : PubMed/NCBI

9 

Colla S, Tagliaferri S, Morandi F, et al: The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: Involvement in myeloma-induced angiogenesis. Blood. 110:4464–4475. 2007. View Article : Google Scholar : PubMed/NCBI

10 

Li J and Li G: Cell cycle regulator ING4 is a suppressor of melanoma angiogenesis that is regulated by the metastasis suppressor BRMS1. Cancer Res. 70:10445–10453. 2010. View Article : Google Scholar : PubMed/NCBI

11 

Kalluri R and Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 112:1776–1784. 2003. View Article : Google Scholar : PubMed/NCBI

12 

Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Mani SA, Guo W, Liao MJ, et al: The epithelial mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI

14 

Santisteban M, Reiman JM, Asiedu MK, et al: Immune-induced epithelial to mesenchymal transition n vivo generates breast cancer stem cells. Cancer Res. 69:2887–2895. 2009. View Article : Google Scholar : PubMed/NCBI

15 

Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI

16 

Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

17 

Song GQ and Zhao Y: Different therapeutic effects of distinct KISS1 fragments on breast cancer n vitro and n vivo. Int J Oncol. 43:1219–1227. 2013.PubMed/NCBI

18 

Lokman NA, Elder AS, Ricciardelli C and Oehler MK: Chick chorioallantoic membrane (CAM) assay as an n vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis. Int J Mol Sci. 13:9959–9970. 2012. View Article : Google Scholar : PubMed/NCBI

19 

Apte U, Zeng G, Thompson MD, et al: beta-Catenin is critical for early postnatal liver growth. Am J Physiol Gastrointest Liver Physiol. 292:G1578–G1585. 2007. View Article : Google Scholar : PubMed/NCBI

20 

Nejak-Bowen K and Monga SP: Wnt/beta-catenin signaling in hepatic organogenesis. Organogenesis. 4:92–99. 2008. View Article : Google Scholar : PubMed/NCBI

21 

Brown AM: Wnt signaling in breast cancer: Have we come full circle? Breast Cancer Res. 3:351–355. 2001. View Article : Google Scholar : PubMed/NCBI

22 

Li J and Zhou BP: Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer. 11:492011. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Wang CJ, Yang D and Luo YW: Recombinant ING4 suppresses the migration of SW579 thyroid cancer cells via epithelial to mesenchymal transition. Exp Ther Med 10: 603-607, 2015.
APA
Wang, C., Yang, D., & Luo, Y. (2015). Recombinant ING4 suppresses the migration of SW579 thyroid cancer cells via epithelial to mesenchymal transition. Experimental and Therapeutic Medicine, 10, 603-607. https://doi.org/10.3892/etm.2015.2515
MLA
Wang, C., Yang, D., Luo, Y."Recombinant ING4 suppresses the migration of SW579 thyroid cancer cells via epithelial to mesenchymal transition". Experimental and Therapeutic Medicine 10.2 (2015): 603-607.
Chicago
Wang, C., Yang, D., Luo, Y."Recombinant ING4 suppresses the migration of SW579 thyroid cancer cells via epithelial to mesenchymal transition". Experimental and Therapeutic Medicine 10, no. 2 (2015): 603-607. https://doi.org/10.3892/etm.2015.2515
Copy and paste a formatted citation
x
Spandidos Publications style
Wang CJ, Yang D and Luo YW: Recombinant ING4 suppresses the migration of SW579 thyroid cancer cells via epithelial to mesenchymal transition. Exp Ther Med 10: 603-607, 2015.
APA
Wang, C., Yang, D., & Luo, Y. (2015). Recombinant ING4 suppresses the migration of SW579 thyroid cancer cells via epithelial to mesenchymal transition. Experimental and Therapeutic Medicine, 10, 603-607. https://doi.org/10.3892/etm.2015.2515
MLA
Wang, C., Yang, D., Luo, Y."Recombinant ING4 suppresses the migration of SW579 thyroid cancer cells via epithelial to mesenchymal transition". Experimental and Therapeutic Medicine 10.2 (2015): 603-607.
Chicago
Wang, C., Yang, D., Luo, Y."Recombinant ING4 suppresses the migration of SW579 thyroid cancer cells via epithelial to mesenchymal transition". Experimental and Therapeutic Medicine 10, no. 2 (2015): 603-607. https://doi.org/10.3892/etm.2015.2515
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team